Dermata Receives Approval From FDA For The Proprietary Name Xyngari For Its Phase 3 Acne Candidate
Dermata Receives Approval From FDA For The Proprietary Name Xyngari For Its Phase 3 Acne Candidate
Dermata獲得FDA批准，將其3期痤瘡候選藥物命名爲Xyngari
Dermata Receives Approval From FDA For The Proprietary Name Xyngari For Its Phase 3 Acne Candidate
Dermata獲得FDA批准，將其3期痤瘡候選藥物命名爲Xyngari
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間